4-butyrolactone has been researched along with Fibrosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Dong, Z; Ma, X; Wang, X; Yang, D | 1 |
| Chen, TQ; Deng, YF; Mao, LN; Ming, JX; Ren, H; Sun, WG; Wang, YF; Xu, QQ; Zhang, YH; Zhou, JJ; Zhou, Q | 1 |
| Ekenseair, AK; Mikos, AG; Roh, TT; Spicer, PP; Tzouanas, SN; Vo, TN; Watson, BM | 1 |
3 other study(ies) available for 4-butyrolactone and Fibrosis
| Article | Year |
|---|---|
Alleviation of glucolipotoxicity-incurred cardiomyocyte dysfunction by Z-ligustilide involves in the suppression of oxidative insult, inflammation and fibrosis.
Topics: 4-Butyrolactone; Animals; Apoptosis; Cell Survival; Cells, Cultured; Fibrosis; Inflammation; Molecular Structure; Myocytes, Cardiac; Oxidation-Reduction; Rats | 2021 |
Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-κB/NLRP3 signaling pathway.
Topics: 4-Butyrolactone; Animals; Fibrosis; Inflammation; Lipopolysaccharides; Liver; Methionine; Mice; Mice, Inbred C57BL; Monosaccharides; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease; Signal Transduction; Transforming Growth Factor beta1 | 2022 |
In vitro and in vivo evaluation of self-mineralization and biocompatibility of injectable, dual-gelling hydrogels for bone tissue engineering.
Topics: 4-Butyrolactone; Acrylates; Acrylic Resins; Animals; Biocompatible Materials; Calcification, Physiologic; Calcium; Cross-Linking Reagents; Fibrosis; Hydrogels; Hydrolysis; Hydrophobic and Hydrophilic Interactions; Injections; Materials Testing; Osteogenesis; Protein Glutamine gamma Glutamyltransferase 2; Rats, Inbred F344; Skull; Temperature; Time Factors; Tissue Engineering; Tissue Scaffolds; X-Ray Microtomography | 2015 |